Hans Kaspar Binz

Hans Kaspar Binz

Auto-generated profile, based on publicly available information

Hans Kaspar Binz

Molecular Partners AG, Zurich-Schlieren, Switzerland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2004 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
HBH Kaspar Binz
H Kaspar Binz
PAPatrick Amstutz
Patrick Amstutz
AKAndreas Kohl
Andreas Kohl
MSMichael T Stumpp
Michael T Stumpp
CBChristophe Briand
Christophe Briand
APAndreas Plückthun
Andreas Plückthun

6 October 2005 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
HBH Kaspar Binz
H Kaspar Binz
PAPatrick Amstutz
Patrick Amstutz
APAndreas Plückthun
Andreas Plückthun

1 September 2003 in Journal of Molecular Biology
Verified
Journal Article
Closed access
HBH.KAspar Binz
H.KAspar Binz
MSMichael T Stumpp
Michael T Stumpp
PFPatrik Forrer
Patrik Forrer
PAPatrick Amstutz
Patrick Amstutz
APAndreas Plückthun
Andreas Plückthun

3 February 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
AKAndreas Kohl
Andreas Kohl
HBH. Kaspar Binz
H. Kaspar Binz
PFPatrik Forrer
Patrik Forrer
MSMichael T. Stumpp
Michael T. Stumpp
APAndreas Plückthun
Andreas Plückthun
MGMarkus G. Grütter
Markus G. Grütter
Ankyrin repeat (AR) proteins mediate innumerable protein–protein interactions in virtually all phyla. This finding suggested the use of AR proteins as designed binding molecules. Based on sequence and structural analyses, we designed a consensus AR with fixed framework and randomized interacting residues. We generated several combinatorial libraries of AR proteins consisting of defined numbers of this repeat. Randomly chosen library members are expressed in soluble form in the cytoplasm ofEscherichia coliconstituting up to 30% of total cellular protein and show high thermodynamic stability. We determined the crystal structure of one of those library members to 2.0-Å resolution, providing insight into the consensus AR fold. Besides the highly complementary hydrophobic repeat–repeat interfaces and the absence of structural irregularities in the consensus AR protein, the regular and extended hydrogen bond networks in the β-turn and loop regions are noteworthy. Furthermore, all residues found in the turn region of the Ramachandran plot are glycines. Many of these features also occur in natural AR proteins, but not in this rigorous and standardized fashion. We conclude that the AR domain fold is an intrinsically very stable and well-expressed scaffold, able to display randomized interacting residues. This scaffold represents an excellent basis for the design of novel binding molecules.

1 August 2008 in Drug Discovery Today
Verified
Journal Article
Closed access
MSMichael T. Stumpp
Michael T. Stumpp
HBH. Kaspar Binz
H. Kaspar Binz
PAPatrick Amstutz
Patrick Amstutz

14 February 2010 in Cancer Research
Verified
Journal Article
Open access
PDF file
CZChristian Zahnd
Christian Zahnd
MKMartin Kawe
Martin Kawe
MSMichael T. Stumpp
Michael T. Stumpp
CPChristine de Pasquale
Christine de Pasquale
RTRastislav Tamaskovic
Rastislav Tamaskovic
APAndreas Plückthun
Andreas Plückthun
Slow-clearing, tumor-targeting proteins such as monoclonal antibodies typically exhibit high tumor accumulation but low tissue contrast, whereas intermediate-sized proteins such as scFvs show faster clearance but only moderate tumor accumulation. For both, tumor targeting does not seem to improve further above an optimal affinity. We show here that with very small high-affinity proteins such as designed ankyrin repeat proteins (DARPins), these limits can be overcome. We have systematically investigated the influence of molecular mass and affinity on tumor accumulation with DARPins with specificity for HER2 in SK-OV-3.ip nude mouse xenografts. DARPins with a mass of 14.5 kDa and affinities between 270 nmol/L and 90 pmol/L showed a strong correlation of tumor accumulation with affinity to HER2, with the highest affinity DARPin reaching 8% ID/g after 24 hours and 6.5% ID/g after 48 hours (tumor-to-blood ratio >60). Tumor autoradiographs showed good penetration throughout the tumor mass. Genetic fusion of two DARPins (30 kDa) resulted in significantly lower tumor accumulation, similar to values observed for scFvs, whereas valency had no influence on accumulation. PEGylation of the DARPins increased the circulation half-life, leading to higher tumor accumulation (13.4% ID/g after 24 hours) but lower tumor-to-blood ratios. Affinity was less important for tumor uptake of the PEGylated constructs. We conclude that two regimes exist for delivering high levels of drug to a tumor: small proteins with very high affinity, such as unmodified DARPins, and large proteins with extended half-life, such as PEGylated DARPins, in which the importance of affinity is less pronounced. Cancer Res; 70(4); 1595–605